[HTML][HTML] Molecular targeted therapy for anticancer treatment
HY Min, HY Lee - Experimental & molecular medicine, 2022 - nature.com
Since the initial clinical approval in the late 1990s and remarkable anticancer effects for
certain types of cancer, molecular targeted therapy utilizing small molecule agents or …
certain types of cancer, molecular targeted therapy utilizing small molecule agents or …
[HTML][HTML] The path to the clinic: a comprehensive review on direct KRASG12C inhibitors
The RAS oncogene is both the most frequently mutated oncogene in human cancer and the
first confirmed human oncogene to be discovered in 1982. After decades of research, in …
first confirmed human oncogene to be discovered in 1982. After decades of research, in …
[HTML][HTML] MAPK/ERK signaling pathway in hepatocellular carcinoma
H Moon, SW Ro - Cancers, 2021 - mdpi.com
Simple Summary The mitogen-activated protein kinase/extracellular signal-regulated kinase
(MAPK/ERK) signaling pathway is frequently activated in liver cancer, which is one of the …
(MAPK/ERK) signaling pathway is frequently activated in liver cancer, which is one of the …
KRAS mutation in pancreatic cancer
J Luo - Seminars in oncology, 2021 - Elsevier
Pancreatic cancer is a recalcitrant cancer with one of the lowest 5-year survival rates. A
hallmark of pancreatic cancer is the prevalence of oncogenic mutation in the KRAS gene …
hallmark of pancreatic cancer is the prevalence of oncogenic mutation in the KRAS gene …
[HTML][HTML] Learning single-cell perturbation responses using neural optimal transport
Understanding and predicting molecular responses in single cells upon chemical, genetic or
mechanical perturbations is a core question in biology. Obtaining single-cell measurements …
mechanical perturbations is a core question in biology. Obtaining single-cell measurements …
Decrypting drug actions and protein modifications by dose-and time-resolved proteomics
Although most cancer drugs modulate the activities of cellular pathways by changing
posttranslational modifications (PTMs), little is known regarding the extent and the time-and …
posttranslational modifications (PTMs), little is known regarding the extent and the time-and …
BRAF—A tumour-agnostic drug target with lineage-specific dependencies
In June 2022, the FDA granted Accelerated Approval to the BRAF inhibitor dabrafenib in
combination with the MEK inhibitor trametinib for the treatment of adult and paediatric …
combination with the MEK inhibitor trametinib for the treatment of adult and paediatric …
Combinatorial strategies to target RAS-driven cancers
N Perurena, L Situ, K Cichowski - Nature Reviews Cancer, 2024 - nature.com
Although RAS was formerly considered undruggable, various agents that inhibit RAS or
specific RAS oncoproteins have now been developed. Indeed, the importance of directly …
specific RAS oncoproteins have now been developed. Indeed, the importance of directly …
Coordinated transcriptional and catabolic programs support iron-dependent adaptation to RAS–MAPK pathway inhibition in pancreatic cancer
M Ravichandran, J Hu, C Cai, NP Ward, A Venida… - Cancer discovery, 2022 - AACR
The mechanisms underlying metabolic adaptation of pancreatic ductal adenocarcinoma
(PDA) cells to pharmacologic inhibition of RAS–MAPK signaling are largely unknown. Using …
(PDA) cells to pharmacologic inhibition of RAS–MAPK signaling are largely unknown. Using …
PINK1-mediated mitophagy promotes oxidative phosphorylation and redox homeostasis to induce drug-tolerant persister cancer cells
Y Li, H Chen, X Xie, B Yang, X Wang, J Zhang, T Qiao… - Cancer Research, 2023 - AACR
The drug-tolerant persister (DTP) state enables cancer cells to evade cytotoxic stress from
anticancer therapy. However, the mechanisms governing DTP generation remain poorly …
anticancer therapy. However, the mechanisms governing DTP generation remain poorly …